Search results for Losatuxizumab

Losatuxizumab Biosimilar – Research Grade mAb, ProteoGenix, PX-TA1457-

Losatuxizumab, Abbexa, abx831415

Losatuxizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting EGFR, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Losatuxizumab ELISA Kit, ProteoGenix, KPTX121

Description of Losatuxizumab ELISA Kit Losatuxizumab ELISA Kit: Structure, Activity, and Application Introduction Losatuxizumab is a novel antibody that has shown promising results in the treatment of various cancers. It specifically targets the tumor-associated glycoprotein 72 (TAG-72), which is overexpressed in many types of cancer cells. In order to accurately measure the levels of losatuxizumab in biological samples, an enzyme-linked immunosorbent assay (ELISA) kit has been developed. This kit provides a reliable and sensitive method for quantifying losatuxizumab levels, making it a valuable tool for both research and clinical applications. Structure of Losatuxizumab Losatuxizumab is a monoclonal antibody, meaning it is produced by a single type of immune cell. It is composed of two heavy chains and two light chains, each with a specific amino acid sequence. The heavy chains are connected by disulfide bonds and the light chains are connected to the heavy chains by non-covalent interactions. The variable regions of the antibody, also known as the antigen-binding sites, are responsible for binding to the specific target, TAG-72. The constant region of the antibody, on the other hand, determines the antibody’s effector functions. Losatuxizumab belongs to the IgG1 subclass, which is known for its ability to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This means that losatuxizumab can recruit immune cells and activate the complement system to destroy cancer cells that express TAG-72. Activity of Losatuxizumab The main activity of losatuxizumab is to bind to TAG-72, a cell surface glycoprotein that is highly expressed in various types of cancer cells, including ovarian, breast, and colorectal cancer. TAG-72 is not expressed in normal tissues, making it an ideal therapeutic target for cancer treatment. By binding to TAG-72, losatuxizumab can block the interaction between TAG-72 and its ligands, which are involved in cell adhesion, migration, and proliferation. This ultimately leads to the inhibition of tumor growth and metastasis. In addition, losatuxizumab can also activate the immune system to directly attack cancer cells. Through its effector functions, it can induce the destruction of cancer cells by recruiting natural killer (NK) cells, macrophages, and other immune cells. This mechanism of action makes losatuxizumab a promising immunotherapy for cancer treatment. Application of Losatuxizumab ELISA Kit The Losatuxizumab ELISA Kit is a valuable tool for measuring the levels of losatuxizumab in biological samples. It is a highly sensitive and specific assay that can accurately detect and quantify losatuxizumab in serum, plasma, and other biological fluids. This kit is essential for monitoring the pharmacokinetics of losatuxizumab in patients undergoing treatment, as well as for evaluating the efficacy of the drug. The Losatuxizumab ELISA Kit can also be used in research studies to investigate the pharmacodynamics of losatuxizumab and its mechanism of action. By measuring the levels of losatuxizumab in different samples, researchers can gain a better understanding of how the drug is distributed and eliminated in the body, as well as its effect on TAG-72 expression and cancer cell activity. In addition, the Losatuxizumab ELISA Kit can be used in the development of new drugs and therapies that target TAG-72. By accurately measuring the levels of losatuxizumab in different samples, researchers can determine the optimal dosage and dosing schedule for maximum efficacy and minimal side effects.

Losatuxizumab ELISA Kit, Abbexa, abx395010

Losatuxizumab ELISA Kit is a quantitative ELISA kit for detection of Losatuxizumab.Losatuxizumab is a biosimilar that targets EGFR. EGFR (Epidermal growth factor receptor, HER1, ErbB1) is encoded by the EGFR gene located on chromosome 7 in humans. EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. Phosphorylation of EGFR at certain residues is also mediated by Src-non-receptor kinase. EGFR activation signals multiple downstream signaling cascades such as the Ras - ERK, pi3-K - Akt, Jak - STAT and PKC pathways that help in growth and proliferation of cells. Phosphorylation of EGFR at Y1086 specifically allows binding of the adaptor protein GRB2, leading to activation of the MAPK pathway. Upon receptor activation and signaling, EGFR is endocytosed and targeted for degradation or recycling. Mutations in the EGFR gene are associated with lung cancer and multiple alternatively spliced transcript variants encode different protein isoforms of EGFR have been found. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. Moreover, EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

Losatuxizumab Biosimilar - Research Grade, ichor.bio, ICH5657